SAN DIEGO, Sept. 27, 2016 /PRNewswire/ -- Ansun BioPharma announced today the publication of two reports by researchers showing potent inhibitory effect of DAS181 on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
"DAS181 Blocks Respiratory Syncytia Virus Infection of Hep-2 Cells" was published in the peer reviewed Journal of Antivirals & Antiretrovirals was published by Dr. Guy Boivin and colleagues at CHU de Quebec and Université Laval, Quebec City, QC, Canada. Respiratory Syncytial Virus (RSV) is one of the most common respiratory viruses affecting hospitalized and immunocompromised patients. Current therapeutic options are limited for the treatment of RSV. Strong inhibition of RSV by DAS181 was observed in the published in-vitro experiments. Lower concentrations of DAS181 were required to inhibit the virus, compared to Ribavirin, the only current approved treatment.
The article can be found on line at:
Additionally, another study was performed that showed that DAS181 showed activity against human metapneumovirus, a related respiratory virus. "Effect of Sialidase Fusion Protein (DAS 181) on Human Metapneumovirus (hMPV) Infection of Hep-2 Cells" was published by Dr. David Gordin and colleagues at Flinders University of Australia in the Journal of Antiviral Chemistry and Chemotherapy. The published data suggested potent in-vitro inhibition of Metapneumovus by DAS181. Metapneumovirus is a common respiratory virus in children and immunocompromised adults. Currently there are no treatments available for hMPV infections.
The manuscript can be found on line at:
Dr. Ronald Moss, CEO of Ansun commented on the recent publications: "Although our current clinical focus is the testing of DAS181 against parainfluenza virus in immunocompromised patients, the potential to utilize the same antiviral against other respiratory viruses could be important. We are hoping to examine the clinical potential of DAS181 against RSV and hMPV in the near term."
About Ansun BioPharma
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two programs in late stage clinical development, both involving DAS181, an investigational host directed antiviral. FluDaseTM (DAS181) is a first-in-class broad-spectrum investigational therapeutic agent in phase 2 development for the treatment of influenza. ParaDaseTM (DAS181) is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track and Orphan Designation by the U.S. FDA. No current antivirals are licensed for the treatment of parainfluenza infection. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ansun-biopharma-announces-two-publications-showing-inhibitory-effects-of-das181-on-respiratory-syncytial-virus-rsv-and-human-metapneumovirus-hmpv-300334472.html
SOURCE Ansun BioPharma